Genzyme Targets Sandoz Over Kidney Drug ANDA

Law360, New York (June 29, 2010, 9:25 AM EDT) -- Sandoz Inc., the generics arm of Novartis AG, is facing a patent infringement suit from Genzyme Corp. over an abbreviated new drug application for an off-brand version of kidney disease treatment Renvela.

Genzyme lodged its complaint Friday in the U.S. District Court for the District of Maryland, asking the court to enjoin Sandoz from developing its proposed generic until the expiration of U.S. Patent Number 5,667,775.

A generic version of Renvela would infringe the plaintiff's exclusive right to sell the drug, according to the complaint....
To view the full article, register now.